Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label TrialSikander Ailawadhi, Yifan Zhai, Mary C. Collins et al.|Clinical Cancer Research|2023Cited by 38
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Clinical Cancer Research|2023Cited by 24